Drug General Information
Drug ID
D0A7NZ
Former ID
DIB011505
Drug Name
CNTO-6785
Drug Type
Antibody
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [524385]
Company
Janssen research & development
Target and Pathway
Target(s) Interleukin-17 Target Info [525413]
KEGG Pathway Cytokine-cytokine receptor interaction
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL23-mediated signaling events
WikiPathways TCR Signaling Pathway
Allograft Rejection
IL17 signaling pathway
References
Ref 524385ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health.
Ref 525413Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. doi: 10.1038/nrd4518.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.